6-Month interim safety, tolerability, and efficacy of bexicaserin in participants with developmental and epileptic encephalopathies: phase 1b/2a PACIFIC open-label extension

Key Points

• Participants experienced improved safety and tolerability with bexicaserin over six months, with minimal adverse effects.
• The study highlights bexicaserin's effect on measures related to developmental and epileptic disorders, indicating positive responses.
• This observational analysis employs an open-label extension design to capture data on treatment effects across a varied population.
• Findings suggest potential for broad application in managing developmental and epileptic encephalopathy, highlighting further validation needs.